



Medtronic

NEWS RELEASE

Contacts:

Amanda Sheldon
Public Relations
+1-818-576-4826

Jeff Warren
Investor Relations
+1-763-505-2696

FOR IMMEDIATE RELEASE

MEDTRONIC RECEIVES FDA CLEARANCE OF MINIMED® CONNECT FOR MORE CONVENIENT ACCESS TO PERSONAL DIABETES DATA

People with Diabetes and Their Loved Ones Will Have Smartphone Access to Diabetes Information; Healthcare Teams Have More Convenient Data Access with Daily Uploads

BOSTON – June 5, 2015 – Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) clearance of MiniMed® Connect. Designed to provide a mobile connection to critical information for managing diabetes, MiniMed Connect is the first product to enable people with diabetes to discreetly and conveniently view their insulin pump and continuous glucose monitor (CGM) data on a smartphone and provides remote monitoring and text message notifications for their loved ones. It also gives healthcare teams more convenient access to more comprehensive patient data so they can adjust their patients' care plans. The new product clearance was announced from the American Diabetes Association 75th Scientific Sessions in Boston and will be on display at Booth #437.

MiniMed Connect consists of a small device that easily fits on a keychain or in a pocket, a smartphone app for the person with diabetes, and a web display on desktop or mobile devices for their care partners. The MiniMed Connect device securely transmits pump and sensor glucose data from the patient's MiniMed insulin pump to the app and web

display, which shows real-time sensor glucose and insulin information on the phone or any Internet-enabled device anytime, anywhere. The system also delivers preset text notifications to loved ones when the person with diabetes' glucose values go too high or too low, or when an alarm on the pump isn't cleared, providing greater peace of mind for care partners. In addition, MiniMed Connect provides healthcare teams with more comprehensive data, and with more convenient access to their patients' diabetes data so they can adjust care plans.

"Engagement from people with diabetes, loved ones and healthcare providers is key to living well with diabetes. With MiniMed Connect, the entire care team can have access to critical diabetes data to inform the decisions that help people have better outcomes," said Annette Bröls, vice president and general manager, Diabetes Services and Solutions at Medtronic. "MiniMed Connect is another step in our broader strategy to be a holistic diabetes management company. The Connect platform represents how we will use leadership technologies, data and informatics to enable better therapy decision making and care for people with diabetes. Our hope is that this will make it easier for more people to manage their disease and optimize their therapy so they can achieve greater freedom and better health."

The MiniMed Connect remote web display will be available with iOS, Android, or any other Internet-enabled devices. The related smartphone app will initially be available with iOS devices. Samsung is working with Medtronic to also develop an app for Android and optimized experiences on Samsung mobile devices.

MiniMed Connect, which is a secondary display device, is compatible with both the MiniMed® 530G system and the MiniMed® Revel™ system. The product is expected to be available this fall. People with diabetes can visit

www.medtronicdiabetes.com/minimed-connect to sign up to be notified when the product is available.

Multimedia Release

A multimedia version of this release, with downloadable graphics can be found at: <http://bit.ly/1AQytqk>

About the Diabetes Group at Medtronic (www.medtronicdiabetes.com)

Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

About Medtronic

Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-